Table 2.
Demographics and Baseline Characteristics of Patients With MM Enrolled in the LTF Study
| Variable/Statistics | Placebo (n = 72) | Plerixafor (n = 91) | Total (n = 163) |
|---|---|---|---|
| Sex, n (%) | |||
| Male | 53 (74) | 64 (70) | 117 (72) |
| Female | 19 (26) | 27 (30) | 46 (28) |
| Ethnic origin, n (%) | |||
| Caucasian | 60 (83) | 73 (80) | 133 (82) |
| African-American | 6 (8) | 11 (12) | 17 (10) |
| Asian | 1 (1) | 1 (1) | 2 (1) |
| Hispanic/Latino | 2 (3) | 5 (5) | 7 (4) |
| Other | 3 (4) | 1 (1) | 4 (2) |
| Age (y) | |||
| Mean (SD) | 59.3 (9.06) | 59.6 (8.18) | 59.4 (8.56) |
| Median | 62.0 | 60.0 | 61.0 |
| Min, Max | 28, 74 | 37, 76 | 28, 76 |
| Weight (kg) | |||
| Mean (SD) | 87.3 (18.51) | 84.4 (18.48) | 85.7 (18.49) |
| Median | 85.1 | 84.5 | 84.8 |
| Min, Max | 53.1, 130.6 | 48.1, 135.5 | 48.1, 135.5 |
| Underwent auto-HSCT following treatment and apheresis, n (%) | 72 (100) | 91 (100) | 163 (100) |
| Disease stage at baseline*, n (%) | |||
| I | 8 (11) | 15 (16) | 23 (14) |
| II | 18 (25) | 16 (18) | 34 (21) |
| III | 40 (56) | 50 (55) | 90 (55) |
| IV | 0 | 0 | 0 |
| Missing | 6 (8) | 10 (11) | 16 (10) |
| Remission status at baseline*, n (%) | |||
| First/second CR | 11 (15) | 8 (9) | 19 (12) |
| Relapse/second PR | 61 (85) | 83 (91) | 144 (88) |
| Missing | 0 | 0 | 0 |
*
Baseline represents the point immediately before study drug was administered.
†
The plerixafor group included the patient initially randomized to placebo and subsequently underwent rescue with plerixafor.
Abbreviations: CR, complete remission; HSCT, hematopoietic stem cell transplantation; PR, partial remission; SD, standard deviation.